Shanghai Jiao Tong University's Renji Hospital Team Unveils Promising Therapy for Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease

Professor Ye Shuang's team at Renji Hospital has identified a breakthrough treatment for anti-MDA5-positive dermatomyositis (ADM), a rare but devastating rheumatic disease. Characterized by specific cutaneous manifestations, mild myopathy, and rapidly progressive interstitial lung disease (RP-ILD), ADM-ILD causes progressive respiratory failure with a six-month mortality rate reaching 50%.Predominantly reported in East Asia over the past decade, its poor response to conventional immunotherapy has caused grave concern among both rheumatologists and affected patients."

Through persistent biomarker and mechanistic research, Renji rheumatology team identified tofacitinib—a JAK inhibitor originally approved for rheumatoid arthritis—as a potential targeted therapy. Published in The New England Journal of Medicine, their single-center open-label trial demonstrated significant efficacy. For early-stage MDA5-RPILD (disease duration <3 months, FVC ≥50% predicted) patients, Tofacitinib 5mg twice daily showed 6-month cumulative survival 100% (tofacitinib group) vs 78% (treatment-matched historical controls).

"If systemic lupus erythematosus is the 'wolf' of rheumatology, this disease is the 'tiger'. Our findings do not imply that this clinical challenge has been fully resolved. The core message is the imperative for timely diagnosis and early precision intervention. It must be emphasized that patients presenting with severe respiratory decompensation after delayed referrals continue to face alarmingly high mortality risks.

Nevertheless, our research represents a critical step toward solving this clinical dilemma and crossing a pivotal threshold." Stated Dr. Wang Xiaodong, investigator of the study.